AR013569A1 - NEW IMPROVED FORMULATION FOR TROMBOEMBOLIA TREATMENT - Google Patents

NEW IMPROVED FORMULATION FOR TROMBOEMBOLIA TREATMENT

Info

Publication number
AR013569A1
AR013569A1 ARP970102135A ARP970102135A AR013569A1 AR 013569 A1 AR013569 A1 AR 013569A1 AR P970102135 A ARP970102135 A AR P970102135A AR P970102135 A ARP970102135 A AR P970102135A AR 013569 A1 AR013569 A1 AR 013569A1
Authority
AR
Argentina
Prior art keywords
treatment
tromboembolia
formulation
new improved
improved formulation
Prior art date
Application number
ARP970102135A
Other languages
Spanish (es)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR013569A1 publication Critical patent/AR013569A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una novedosa formulacion farmacéutica que comprende el inhibidor de la trombina HOOC-CH2-(R)-Cgl-Aze-Pab en combinacion con glicéridosde cadena mediana. Un proceso para la preparacion de tal formulacion farmacéutica,el uso de dicha formulacion en eltratamiento de la tromboembolia, asi como un método para tratar un paciente que requiere dicho tratamiento mediante el uso de dichaformulacion.A novel pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH2- (R) -Cgl-Aze-Pab in combination with medium chain glycerides. A process for the preparation of such pharmaceutical formulation, the use of said formulation in the treatment of thromboembolism, as well as a method of treating a patient requiring said treatment through the use of said formulation.

ARP970102135A 1996-05-31 1997-05-20 NEW IMPROVED FORMULATION FOR TROMBOEMBOLIA TREATMENT AR013569A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602145A SE9602145D0 (en) 1996-05-31 1996-05-31 New improved formulation for the treatment of thromboembolism

Publications (1)

Publication Number Publication Date
AR013569A1 true AR013569A1 (en) 2001-01-10

Family

ID=20402816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102135A AR013569A1 (en) 1996-05-31 1997-05-20 NEW IMPROVED FORMULATION FOR TROMBOEMBOLIA TREATMENT

Country Status (14)

Country Link
US (1) US6673365B1 (en)
EP (1) EP1015022B1 (en)
JP (1) JP2000511526A (en)
AR (1) AR013569A1 (en)
AT (1) ATE284706T1 (en)
AU (1) AU722450B2 (en)
CA (1) CA2253410A1 (en)
DE (1) DE69731981T2 (en)
ID (1) ID19472A (en)
NO (1) NO985558L (en)
NZ (1) NZ332788A (en)
SE (1) SE9602145D0 (en)
WO (1) WO1997045138A1 (en)
ZA (1) ZA974386B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
SE0203349D0 (en) * 2002-11-12 2002-11-12 Astrazeneca Ab New use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464175A (en) * 1982-08-25 1984-08-07 Altman Alan R Multipurpose tamponade and thrombosclerotherapy tube
US4568545A (en) * 1982-10-02 1986-02-04 Amano Seiyaku Kabushiki Kaisha Thrombolytic agent
WO1994007472A1 (en) 1992-10-02 1994-04-14 Pfizer Inc. Pharmaceutical compositions containing nonionic surfactants
SE9301916D0 (en) * 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDES DERIVATIVES
SE9302135D0 (en) 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
SE9404196D0 (en) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation

Also Published As

Publication number Publication date
NO985558D0 (en) 1998-11-27
CA2253410A1 (en) 1997-12-04
ID19472A (en) 1998-07-16
NO985558L (en) 1998-11-27
AU3111597A (en) 1998-01-05
DE69731981D1 (en) 2005-01-20
ZA974386B (en) 1997-12-01
ATE284706T1 (en) 2005-01-15
AU722450B2 (en) 2000-08-03
DE69731981T2 (en) 2005-12-22
SE9602145D0 (en) 1996-05-31
EP1015022B1 (en) 2004-12-15
WO1997045138A1 (en) 1997-12-04
JP2000511526A (en) 2000-09-05
NZ332788A (en) 2000-05-26
EP1015022A1 (en) 2000-07-05
US6673365B1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
PA8468401A1 (en) COMPOUNDS FOR THE TREATMENT OF ISCHEMIA
AR002254A1 (en) ANTITHROMBOTIC FORMULATION AND PROCEDURE FOR ITS MANUFACTURE
ECSP055738A (en) ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ- [b, f] -AZEPIN-5-CARBOXAMIDE AND ITS NEW GLASS FORMS
IS2130B (en) Glutamine-thiazolidide and pyrrolidide and their use as dipeptidyl peptidase IV inhibit
EA199800667A1 (en) NEW PHENANTRIDINES
GB9818916D0 (en) Use
ES2063102T3 (en) IMIDAZOLES FOR THE TREATMENT OF Atherosclerosis.
EE9700225A (en) A method of treating diabetes mellitus using KKF
ATE333896T1 (en) VASCULARIZATION INHIBITORS
ES2178851T3 (en) PROCEDURE FOR THE TREATMENT OF AN ARTICLE CONTAINING AN OXIDABLE ORGANIC COMPOUND.
ES2083597T3 (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PROLONGED COAGULATION TIME.
AR024998A1 (en) NEW RETINOIDS FOR THE TREATMENT OF THE DISEASE
CO4820418A1 (en) METHOD FOR THE TREATMENT OF SUBSTRATES AND ACTIVATION OF BLEACHERS
ES2172171T3 (en) MEDICINAL PRODUCT, CONTAINING YOHIMBINE AND ARGININE, FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS.
ES2167678T3 (en) TREATMENT AND PROFILAXIS OF PANCREATITIS.
ES2184341T3 (en) A METHOD FOR THE PREVENTION AND TREATMENT OF Myocardium Dysfunction.
AR013569A1 (en) NEW IMPROVED FORMULATION FOR TROMBOEMBOLIA TREATMENT
UY26648A1 (en) VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION
ATE215941T1 (en) ISOFLAVONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
ATE323493T1 (en) CONTROLLED RELEASE OF ANTIDEPRESSANTS
AR031404A1 (en) A COMPOSITION AND APPLICATION METHOD
ES2190581T3 (en) 2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT, ACTIVE IN THE PREVENTION AND TREATMENT OF SEPTIC SHOCK.
AR018321A1 (en) A DOSAGE FORM OF PROLONGED LIBERATION THAT INCLUDES OXIBUTININE AND THE USES OF OXIBUTININE AND THE DOSAGE FORM OF PROLONGED LIBERATION.
ES2183205T3 (en) HCG AND DERIVATIVES IN QUALITY OF INHIBITORS OF MELALOPROTEASAS DE LA MATRIZ.
ATE270113T1 (en) COMPOSITIONS FOR IMPROVED WOUND HEALING

Legal Events

Date Code Title Description
FA Abandonment or withdrawal